冰轮环境技术股份有限公司 2025 年半年度报告全文 冰轮环境技术股份有限公司 2025 年半年度报告全文 冰轮环境技术股份有限公司 2025 年半年度报告 【2025 年 8 月】 冰轮环境技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李增群、主管会计工作负责人吴利利及会计机构负责人(会计 主管人员)吴利利声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司不存在对公司未来发展战略和经营目标的实现产生不利影响的重大风 险，公司已在本报告第三节管理层讨论与分析公司面临的风险和应对措施中 披露了公司面对的风险因素及采取的应对措施，敬请查阅。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 | | | | 第一节 | 重要提示、目录和释义 | | 1 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 5 ...

深圳市核达中远通电源技术股份有限公司 2025 年半年度报告全文 证券代码：301516 证券简称：中远通 公告编号：2025-045 深圳市核达中远通电源技术股份有限公司 2025 年半年度报告 2025 年 8 月 深圳市核达中远通电源技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人吉学龙、主管会计工作负责人闪文晓及会计机构负责人（会计主管人员） 闫红卫声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成本公司对投资者的实质承诺，请投资者注 意投资风险。本报告"第三节 管理层讨论与分析"中，详细描述了公司可能面对的风险， 敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 7 | | ...

陕西宝光真空电器股份有限公司2025 年半年度报告 公司代码：600379 公司简称：宝光股份 陕西宝光真空电器股份有限公司 2025 年半年度报告 1 / 138 陕西宝光真空电器股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人谢洪涛、主管会计工作负责人付曙光及会计机构负责人（会计主管人员）袁卫 孝声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 为夯实"长期、稳定、可持续"股东价值回报机制，切实增强投资者获得感，在兼顾公司长 远发展的同时，依据法律法规、规范性文件、《公司章程》等规定及公司2024年年度股东大会对 2025年中期现金分红事项的授权，公司在2025年上半年持续盈利且累计未分配利润为正，现金流 可以满足正常经营和持续发展的情况下，拟定2025年半年度利润分配方案： 拟向全体股东每10股派 ...

杭州星帅尔电器股份有限公司 2025 年半年度报告全文 杭州星帅尔电器股份有限公司 2025 年半年度报告 2025-094 2025 年 8 月 1 杭州星帅尔电器股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人楼勇伟、主管会计工作负责人高林锋及会计机构负责人(会计 主管人员)高林锋声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 存在一定的不确定性，投资者及相关人士均应当对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本报告，在本报告第三节"管理层讨论与分析" 中的"十、公司面临的风险和应对措施"部分，描述了公司未来经营可能面 临的主要风险，敬请广大投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示 ...

天际新能源科技股份有限公司 2025 年半年度报告全文 天际新能源科技股份有限公司 TONZE NEW ENERGY TECHNOLOGY CO.,LTD. （广东省汕头市潮汕路金园工业城 12-12 片区） 2025 年半年度报告 二〇二五年八月 1 天际新能源科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人吴锡盾、主管会计工作负责人杨志轩及会计机构负责人(会计 主管人员)陈琼声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中所涉及的发展战略、经营计划等前瞻性陈述属于计划性 事项，不构成公司对投资者的实质承诺，敬请投资者注意投资风险。 公司在本年度报告中详细阐述了未来可能发生的有关风险因素及对策， 详见"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施"， 敬请广大投资者予以关注，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) The Board of Directors and senior management guarantee the report's accuracy and completeness, with all directors attending the review meeting - The company's Board of Directors and senior management guarantee the truthfulness, accuracy, and completeness of the report content, assuming legal responsibility, with all directors attending the board meeting to review this semi-annual report[5](index=5&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the 2025 semi-annual period[6](index=6&type=chunk) - The report contains forward-looking statements about the company's future plans, which do not constitute a substantial commitment to investors, reminding investors to be aware of relevant risks[5](index=5&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) [Company Profile](index=6&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Tonghua Jinma Pharmaceutical Group Co., Ltd. (stock code: 000766) is a company listed on the Shenzhen Stock Exchange, with Zhang Yufu as its legal representative Company Basic Information | Item | Information | | :--- | :--- | | **Stock Abbreviation** | Tonghua Jinma | | **Stock Code** | 000766 | | **Listing Exchange** | Shenzhen Stock Exchange | | **Company Full Chinese Name** | 通化金马药业集团股份有限公司 | | **Legal Representative** | Zhang Yufu | [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Revenue remained stable, but profitability significantly improved, with net profit attributable to shareholders up **34.77%** and non-recurring net profit up **125.07%** Key Financial Indicators | Key Financial Indicators | Current Period (Yuan) | Prior Year Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 649,983,808.44 | 649,181,711.75 | 0.12% | | Net Profit Attributable to Shareholders of Listed Company | 16,803,994.50 | 12,468,342.98 | 34.77% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | 14,407,264.70 | 6,401,376.02 | 125.07% | | Net Cash Flow from Operating Activities | 78,047,568.88 | 38,108,424.15 | 104.80% | | Basic Earnings Per Share (Yuan/share) | 0.0174 | 0.0129 | 34.88% | | Weighted Average Return on Net Assets | 0.74% | 0.54% | 0.20% | | **Asset Indicators** | **End of Current Period (Yuan)** | **End of Prior Year (Yuan)** | **YoY Change (%)** | | Total Assets | 4,536,621,550.02 | 4,483,618,602.64 | 1.18% | | Net Assets Attributable to Shareholders of Listed Company | 2,272,201,739.67 | 2,255,397,745.17 | 0.75% | [Non-recurring Gains and Losses and Amounts](index=7&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled **2.40 million yuan**, mainly from government subsidies, contributing to profit but not from core operations Non-recurring Gains and Losses | Item | Amount (Yuan) | | :--- | :--- | | Government subsidies included in current profit and loss | 2,896,934.90 | | Gains and losses from disposal of non-current assets | -48,350.19 | | Net other non-operating income and expenses | -295,572.80 | | **Total** | **2,396,729.80** | [Management Discussion and Analysis](index=9&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Overview of Main Business](index=9&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company, a pharmaceutical manufacturer, focuses on R&D, production, and sales of drugs across various therapeutic areas, achieving stable revenue and significant profit growth - The company's business covers multiple fields including anti-tumor, microbiology, cardiovascular and cerebrovascular, and heat-clearing and detoxifying drugs, with core products such as Compound Lactobacillus Acidophilus Tablets, Osteo-Gua Extract Preparations, and Xiaojin Pills[28](index=28&type=chunk)[29](index=29&type=chunk)[32](index=32&type=chunk) - During the reporting period, the company achieved operating revenue of **650 million yuan**, a year-on-year increase of **0.12%**; net profit attributable to the parent company was **16.80 million yuan**, a year-on-year increase of **34.77%**; and non-recurring net profit attributable to the parent company was **14.41 million yuan**, a year-on-year increase of **125.07%**[37](index=37&type=chunk) - The company's independently developed National Class 1.1 new drug, Amber Octahydroacridine Tablets (for the treatment of Alzheimer's disease), has received the "Acceptance Notice" for its marketing application from the National Medical Products Administration, and the new drug marketing application process is currently underway[39](index=39&type=chunk) [Analysis of Core Competencies](index=12&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) Core competencies include product advantages, technological innovation, comprehensive industrial layout, experienced management team, and effective group control - **Product advantages**: The company offers a complete range of pharmaceutical dosage forms covering multiple therapeutic areas, with several well-known or exclusive products such as Compound Lactobacillus Acidophilus Tablets, Fengshi Qutong Capsules, and Xiaojin Pills[43](index=43&type=chunk) - **Technology advantages**: The company and its subsidiaries hold **45 invention patents** and **76 utility model patents**, with several patents pending, forming an intellectual property protection system for core products[44](index=44&type=chunk) - **Industrial layout advantages**: A business cluster has been formed by the headquarters and multiple subsidiaries, covering R&D and production systems for traditional Chinese medicine, chemical drugs, biological drugs, and innovative drugs, with investments in monoclonal antibody R&D and CRO enterprises[44](index=44&type=chunk) [Analysis of Main Business](index=13&type=section&id=%E4%B8%89%E3%80%81%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Main business revenue structure shifted, with traditional Chinese medicine revenue up **22.11%** and biochemical drug revenue down **9.72%**, while regional performance varied significantly Main Financial Data | Major Financial Data | Current Period (Yuan) | Prior Year Period (Yuan) | YoY Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 649,983,808.44 | 649,181,711.75 | 0.12% | - | | Selling Expenses | 332,382,006.20 | 355,808,947.90 | -6.58% | - | | R&D Investment | 20,780,794.81 | 31,003,332.41 | -32.97% | Due to reduced investment in line with new drug R&D progress in this period | | Net Cash Flow from Operating Activities | 78,047,568.88 | 38,108,424.15 | 104.80% | Due to increased sales collection in this period | | Net Cash Flow from Financing Activities | 420,782.60 | 67,678,006.33 | -99.38% | Due to increased repayment of bank loans compared to the prior year period | Operating Revenue Composition (by Product) | Operating Revenue Composition (by Product) | Current Period Amount (Yuan) | Proportion (%) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Traditional Chinese Medicine | 263,630,295.42 | 40.56% | 22.11% | | Biochemical Drugs | 385,234,419.51 | 59.27% | -9.72% | | APIs | 668,216.37 | 0.10% | -88.98% | Operating Revenue Composition (by Region) | Operating Revenue Composition (by Region) | Current Period Amount (Yuan) | Proportion (%) | YoY Change (%) | | :--- | :--- | :--- | :--- | | North China Region | 149,989,888.87 | 23.08% | 54.42% | | East China Region | 206,011,973.51 | 31.69% | -27.79% | | South China Region | 68,011,518.20 | 10.46% | 55.67% | [Analysis of Non-Main Business](index=14&type=section&id=%E5%9B%9B%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Non-main business items had a minor impact on total profit, with most items being non-recurring, including investment income and fair value changes Non-Main Business Items | Item | Amount (Yuan) | Proportion of Total Profit (%) | Explanation of Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 158,727.11 | 0.66% | Equity method accounting gains/losses and debt restructuring gains/losses | Only equity method accounting gains/losses are sustainable | | Gains and Losses from Changes in Fair Value | -26,262.00 | -0.11% | Due to fluctuations in the fair value of held stocks | Not sustainable | | Asset Impairment | -186,083.51 | -0.77% | Due to provision for inventory depreciation | Sustainable | | Non-operating Income | 365,786.60 | 1.51% | Generated from non-operating activities | Not sustainable | | Non-operating Expenses | 661,359.40 | 2.73% | Generated from non-operating activities | Not sustainable | [Analysis of Assets and Liabilities](index=14&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Total assets increased slightly to **4.54 billion yuan**, with stable asset structure; restricted assets, primarily for loan collateral, totaled **411 million yuan** Asset Items | Asset Item | Period-end Amount (Yuan) | Proportion of Total Assets (%) | Change from Period-start Proportion (%) | | :--- | :--- | :--- | :--- | | Monetary Funds | 343,686,786.24 | 7.58% | 1.46% | | Accounts Receivable | 513,987,637.44 | 11.33% | 0.19% | | Inventories | 367,547,372.85 | 8.10% | -0.42% | | Fixed Assets | 679,776,737.80 | 14.98% | -0.55% | Restricted Assets | Restricted Asset Item | Period-end Book Value (Yuan) | Type of Restriction | Restriction Details | | :--- | :--- | :--- | :--- | | Monetary Funds | 3,586,554.25 | Deposit Freeze | Deposit Freeze | | Fixed Assets | 353,333,116.52 | Mortgage | Loan Mortgage | | Intangible Assets | 54,085,009.69 | Pledge | Loan Pledge | | **Total** | **411,004,680.46** | - | - | [Analysis of Investment Status](index=16&type=section&id=%E5%85%AD%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Investment increased significantly to **9.86 million yuan**, primarily in construction projects for subsidiaries, progressing as planned - The investment amount for the reporting period was **9.86 million yuan**, a year-on-year increase of **348.19%**[60](index=60&type=chunk) Major Investment Projects | Project Name | Investment Method | Amount Invested in Current Period (Yuan) | Cumulative Actual Investment (Yuan) | Project Progress (%) | | :--- | :--- | :--- | :--- | :--- | | Shengtai Bio Phase III Construction Project | Self-built | 497,648.77 | 240,019,748.66 | 96.35% | | Yongkang Pharmaceutical Artificial Breeding Musk Deer Base Construction | Self-built | 5,522,878.29 | 19,335,918.72 | 70.24% | [Analysis of Major Holding and Participating Companies](index=17&type=section&id=%E5%85%AB%E3%80%81%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) Harbin Shengtai Biological Pharmaceutical Co., Ltd., a wholly-owned subsidiary, is a core business unit and major profit contributor, with revenue of **237.70 million yuan** and net profit of **28.52 million yuan** Key Financial Data of Major Subsidiary | Company Name | Company Type | Total Assets (Ten Thousand Yuan) | Net Assets (Ten Thousand Yuan) | Operating Revenue (Ten Thousand Yuan) | Operating Profit (Ten Thousand Yuan) | Net Profit (Ten Thousand Yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Harbin Shengtai Biological Pharmaceutical Co., Ltd. | Subsidiary | 271,934.62 | 76,408.87 | 23,769.68 | 3,647.01 | 2,852.03 | [Risks and Countermeasures](index=18&type=section&id=%E5%8D%81%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces risks from policy changes, new product development, quality control, environmental compliance, and raw material price volatility, addressed by strategic monitoring and management - The company has identified five major risks: * **Pharmaceutical industry policy risk**: Policies such as medical insurance cost control and volume-based procurement create competitive pressure[71](index=71&type=chunk) * **New product development risk**: New drug R&D involves long cycles, high investment, and uncertain success rates[72](index=72&type=chunk) * **Product quality risk**: Complex production processes involve many factors affecting quality[72](index=72&type=chunk) * **Environmental protection and safety production risk**: Increased regulatory requirements lead to higher related expenses[72](index=72&type=chunk) * **Raw material supply and price fluctuation risk**: Macroeconomic environment and environmental policies may affect costs and profitability[72](index=72&type=chunk) [Corporate Governance, Environment, and Society](index=19&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) [Changes in Directors, Supervisors, and Senior Management](index=19&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) Changes in the board of directors and supervisory board occurred, including the departure and election of independent directors, and the departure of supervisors Changes in Directors, Supervisors, and Senior Management | Name | Position Held | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Han Jiajun | Independent Director | Departure | February 10, 2025 | Personal reasons | | Zhao Wei | Independent Director | Elected | April 15, 2025 | Personal reasons | | Xu Changyou | Chairman of Supervisory Board | Departure | June 23, 2025 | Dismissal | | Yin Qiuting | Supervisor | Departure | June 23, 2025 | Dismissal | | Guo Meina | Supervisor | Departure | June 23, 2025 | Dismissal | [Profit Distribution Plan](index=19&type=section&id=%E4%BA%8C%E3%80%81%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E5%8F%8A%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E8%82%A1%E6%9C%AC%E6%83%85%E5%86%B5) The company plans no profit distribution for the 2025 semi-annual period, including no cash dividends, bonus shares, or capital reserve conversions - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[75](index=75&type=chunk) [Environmental Information Disclosure](index=19&type=section&id=%E5%9B%9B%E3%80%81%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E6%83%85%E5%86%B5) The company and its three main subsidiaries are listed as legally required environmental information disclosure enterprises and have complied with disclosure regulations - The listed company and its three main subsidiaries are included in the list of enterprises required to disclose environmental information by law[77](index=77&type=chunk) [Significant Matters](index=21&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Significant Guarantees](index=23&type=section&id=2%E3%80%81%E9%87%8D%E5%A4%A7%E6%8B%85%E4%BF%9D) Total actual guarantees amounted to **1.71 billion yuan**, representing **75.04%** of net assets, all for subsidiaries, with no external violations Significant Guarantees Metrics | Indicator | Amount (Ten Thousand Yuan) | | :--- | :--- | | Total approved guarantee limit at period-end | 202,500 | | Total actual guarantee balance at period-end | 170,500 | | Proportion of actual total guarantees to company's net assets | 75.04% | | Amount of total guarantees exceeding 50% of net assets | 170,500 | - The company's guarantees are all provided to its subsidiaries, primarily Harbin Shengtai Biological Pharmaceutical Co., Ltd. and Chengdu Yongkang Pharmaceutical Co., Ltd.[98](index=98&type=chunk) [Entrusted Wealth Management](index=24&type=section&id=3%E3%80%81%E5%A7%94%E6%89%98%E7%90%86%E8%B4%A2) The company invested **0.96 million yuan** in broker wealth management products using its own funds, with **0.96 million yuan** outstanding, and no principal loss expected Entrusted Wealth Management | Type | Source of Funds | Amount of Entrusted Wealth Management (Ten Thousand Yuan) | Unexpired Balance (Ten Thousand Yuan) | | :--- | :--- | :--- | :--- | | Broker wealth management products | Own funds | 96.35 | 95.8 | [Share Changes and Shareholder Information](index=26&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) [Share Change Status](index=26&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) Total share capital remained unchanged at **966,494,707 shares**, with **99.95%** unrestricted and **0.05%** restricted shares, maintaining a stable structure Share Types | Share Type | Quantity (Shares) | Proportion (%) | | :--- | :--- | :--- | | Restricted Shares | 487,026 | 0.05% | | Unrestricted Shares | 966,007,681 | 99.95% | | **Total Share Capital** | **966,494,707** | **100.00%** | [Shareholder Numbers and Shareholding](index=28&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the reporting period, there were **39,497** common shareholders, with the largest shareholder, Yu Lanjun, holding **19.66%**, mostly pledged - The total number of common shareholders at the end of the reporting period was **39,497**[111](index=111&type=chunk) Top Shareholders | Shareholder Name | Shareholding Proportion (%) | Shareholding Quantity at Period-end (Shares) | Share Status | | :--- | :--- | :--- | :--- | | Yu Lanjun | 19.66% | 190,000,000 | Pledged 150,000,000 | | Sun Changhao | 4.61% | 44,579,900 | Pledged 20,000,000 | | Li Jia | 4.51% | 43,599,900 | Pledged 32,700,000 | | Shanghai Mukai Trading Co., Ltd. | 4.21% | 40,670,000 | - | | Tang Xiaoni | 2.07% | 20,000,000 | Pledged 20,000,000 | | Tonghua Yongxin Investment Co., Ltd. | 2.07% | 20,000,000 | Pledged 10,000,000 | [Bond-Related Information](index=32&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related activities during the reporting period - The company had no bond-related information during the reporting period[118](index=118&type=chunk) [Financial Report](index=33&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section includes the unaudited 2025 semi-annual financial statements, comprising consolidated and parent company balance sheets, income statements, cash flow statements, and notes [Audit Report](index=33&type=section&id=%E4%B8%80%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's 2025 semi-annual financial report is unaudited - The company's semi-annual financial report is unaudited[120](index=120&type=chunk) [Financial Statements](index=33&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the consolidated and parent company financial statements as of June 30, 2025, including balance sheets, income statements, cash flow statements, and statements of changes in equity [Consolidated Balance Sheet](index=33&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, total assets were **4.54 billion yuan**, total liabilities **2.26 billion yuan**, and total equity attributable to parent company owners **2.27 billion yuan** Consolidated Balance Sheet | Item | Period-end Balance (Yuan) | Period-start Balance (Yuan) | | :--- | :--- | :--- | | Total Assets | 4,536,621,550.02 | 4,483,618,602.64 | | Total Liabilities | 2,264,369,984.22 | 2,228,215,680.87 | | Total Equity Attributable to Parent Company Owners | 2,272,201,739.67 | 2,255,397,745.17 | [Consolidated Income Statement](index=37&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In the first half of 2025, total operating revenue was **650 million yuan**, total operating cost **627 million yuan**, total profit **24.20 million yuan**, and net profit **16.85 million yuan** Consolidated Income Statement | Item | Amount for Current Period (Yuan) | Amount for Prior Period (Yuan) | | :--- | :--- | :--- | | I. Total Operating Revenue | 649,983,808.44 | 649,181,711.75 | | II. Total Operating Costs | 627,169,906.10 | 633,776,186.81 | | III. Operating Profit | 24,499,154.24 | 13,911,056.79 | | IV. Total Profit | 24,203,581.44 | 13,569,868.80 | | V. Net Profit | 16,848,644.03 | 12,351,414.08 | | Net Profit Attributable to Parent Company Shareholders | 16,803,994.50 | 12,468,342.98 | [Consolidated Cash Flow Statement](index=41&type=section&id=5%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Net cash flow from operating activities was **78.05 million yuan**, significantly up year-on-year; net cash flow from investing activities was **-12.35 million yuan** Consolidated Cash Flow Statement | Item | Amount for Current Period (Yuan) | Amount for Prior Period (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 78,047,568.88 | 38,108,424.15 | | Net Cash Flow from Investing Activities | -12,351,348.24 | -16,837,671.53 | | Net Cash Flow from Financing Activities | 420,782.60 | 67,678,006.33 | | Net Increase in Cash and Cash Equivalents | 66,117,003.24 | 88,948,758.95 | [Notes to Financial Statements](index=53&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section details the company's basic information, basis of financial statement preparation, accounting policies, taxes, and notes to major consolidated financial statement items - The company operates in the pharmaceutical manufacturing industry, primarily engaged in the R&D, production, and sales of pharmaceutical products, with Yu Lanjun as the actual controller[164](index=164&type=chunk)[165](index=165&type=chunk) - A total of **17 subsidiaries** were included in the scope of consolidation for this period, with no changes compared to the prior period[166](index=166&type=chunk) [Other Submitted Data](index=189&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E5%85%B6%E4%BB%96%E6%8A%A5%E9%80%81%E6%95%B0%E6%8D%AE) [Investor Relations Activities](index=189&type=section&id=%E4%BA%8C%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%8E%A5%E5%BE%85%E8%B0%83%E7%A0%94%E3%80%81%E6%B2%9F%E9%80%9A%E3%80%81%E9%87%87%E8%AE%BF%E7%AD%89%E6%B4%BB%E5%8A%A8%E7%99%BB%E8%AE%B0%E8%A1%A8) The company engaged in multiple investor relations activities through phone and online platforms, discussing new drug progress, annual performance, and strategy - The company conducted a total of **8 investor relations activities** during the reporting period, primarily through phone communication and online platforms, with core discussions revolving around the company's new drug development progress[1017](index=1017&type=chunk)

杭华油墨股份有限公司2025 年半年度报告 公司代码：688571 公司简称：杭华股份 杭华油墨股份有限公司 2025 年半年度报告 1 / 192 杭华油墨股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司在生产经营过程中 可能面临的风险敬请查阅本报告"第三节 管理层讨论与分析"之"四、风险因素"部分内容，请 投资者予以关注。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人邱克家、主管会计工作负责人邱克家及会计机构负责人（会计主管人员）王斌 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的 ...

君禾泵业股份有限公司2025 年半年度报告 公司代码：603617 公司简称：君禾股份 君禾泵业股份有限公司 2025 年半年度报告 √适用 □不适用 1 / 170 君禾泵业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张阿华、主管会计工作负责人范超春及会计机构负责人（会计主管人员）杨凯 妮声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投资者 注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 本报告中详述了可能存在的风 ...

四川雅化实业集团股份有限公司 2025 年半年度报告全文 四川雅化实业集团股份有限公司 2025 年半年度报告 2025-39 2025 年 8 月 18 日 1 四川雅化实业集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人孟岩、主管会计工作负责人杨庆及会计机构负责人(会计主管 人员)周利娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 1 | | --- | | œ 1 | | 第二节 | 公司简介和主要财务指标 9 | | --- | --- | | 第三节 | 管理层讨论与分析 12 | | 第四节 | 公司治理、环境和社会 42 | | 第五节 | 重要事项 46 | | 第六节 | 股份变动及股东情况 53 | | 第七节 | 债券相关情况 59 | | 第八节 | 财务报告 60 | | 第 ...

横店影视股份有限公司2025 年半年度报告 公司代码：603103 公司简称：横店影视 横店影视股份有限公司 2025 年半年度报告 1 / 163 横店影视股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张义兵、主管会计工作负责人刘胜波及会计机构负责人（会计主管人员）刘广 仁声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告中有涉及公司经营和发展战略等未来计划的前瞻性陈述，该计划不构成公司对 投资者的实质承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 ...